Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication. 

Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.

21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 16 Mar 2018
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, recently received the National Pharmaceutical Regulatory Agency’s approval for an update on its indication.